| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/22/2006 | CA2590932A1 Thiazolium compounds and uses thereof |
| 06/22/2006 | CA2590903A1 Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation |
| 06/22/2006 | CA2590883A1 Medicinal composition for treating diabetes |
| 06/22/2006 | CA2590881A1 Silicon compounds and their use |
| 06/22/2006 | CA2590877A1 Silicon compounds and their use |
| 06/22/2006 | CA2590849A1 Alcohol metabolism enhancing agent and alcoholic beverage |
| 06/22/2006 | CA2590845A1 Novel hydantoin derivatives as metalloproteinase inhibitors |
| 06/22/2006 | CA2590843A1 Novel hydantoin derivatives as metalloproteinase inhibitors |
| 06/22/2006 | CA2590841A1 Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
| 06/22/2006 | CA2590838A1 Preventive or therapeutic agent for sleep disorder |
| 06/22/2006 | CA2590768A1 Rnai modulation of mll-af4 and uses thereof |
| 06/22/2006 | CA2590751A1 Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| 06/22/2006 | CA2590619A1 Casein kinase 2 antisense therapy |
| 06/22/2006 | CA2590479A1 Triazole substituted aminobenzophenone compounds |
| 06/22/2006 | CA2590431A1 Novel pharmaceutical composition containing at least one dolastatin 10 derivative |
| 06/22/2006 | CA2590405A1 Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them |
| 06/22/2006 | CA2590396A1 Meta-substituted thiazolidinones, their production and use as pharmaceutical agents |
| 06/22/2006 | CA2590391A1 Use of ppar agonists for the treatment of congestive heart failure |
| 06/22/2006 | CA2590369A1 Compositions comprising sclareol or derivatives thereof and uses thereof |
| 06/22/2006 | CA2590339A1 Piperazinyl pyridine derivatives as anti-obesity agents |
| 06/22/2006 | CA2590333A1 Tetracyclic imidazo-benzodiazepines as gaba receptors modulators |
| 06/22/2006 | CA2590330A1 Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use |
| 06/22/2006 | CA2590316A1 Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease |
| 06/22/2006 | CA2590299A1 Piperazinyl-pyridine analogues |
| 06/22/2006 | CA2590294A1 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| 06/22/2006 | CA2590288A1 Pharmaceutical compositions for the treatment of cellulite |
| 06/22/2006 | CA2590287A1 Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| 06/22/2006 | CA2590278A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| 06/22/2006 | CA2590258A1 Novel uses for estrogen beta agonists |
| 06/22/2006 | CA2590250A1 Pyrimidine inhibitors of erk protein kinase and uses therof |
| 06/22/2006 | CA2590233A1 Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| 06/22/2006 | CA2590229A1 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | CA2590226A1 N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | CA2590222A1 Heterocycloalkyl-benzyl substituted hydroxyethlamines |
| 06/22/2006 | CA2590182A1 Indolomorphinan derivatives having carboxy at the 6'-position |
| 06/22/2006 | CA2590157A1 Solid forms of a chemokine receptor antagonist and methods of use thereof |
| 06/22/2006 | CA2590039A1 Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists |
| 06/22/2006 | CA2590024A1 Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome |
| 06/22/2006 | CA2589995A1 Oxaloacetate, oxaloacetic acid, and oxaloacetate salts for treating cancer |
| 06/22/2006 | CA2589992A1 Treatment of solid cancers |
| 06/22/2006 | CA2589975A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 06/22/2006 | CA2589886A1 Crystalline forms of a factor xa inhibitor |
| 06/22/2006 | CA2589793A1 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| 06/22/2006 | CA2589777A1 Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
| 06/22/2006 | CA2589695A1 Thiazolopyridinone derivates as mch receptor antagonists |
| 06/22/2006 | CA2589678A1 Novel mch receptor antagonists |
| 06/22/2006 | CA2589529A1 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof |
| 06/22/2006 | CA2589527A1 Pyridazinone compounds |
| 06/22/2006 | CA2589525A1 Hydantoin derivatives useful as metalloproteinase inhibitors |
| 06/22/2006 | CA2589521A1 Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers |
| 06/22/2006 | CA2589519A1 Tri (hydroxymethyl) methylamine salt or an ethanol amine salt of (2s) -2-ethoxy-3- (4-{2- [hexyl (2- phenylethyl) amino] - 2 -oxoethoxy} phenyl) propanoic acid |
| 06/22/2006 | CA2589501A1 Indolinones and their use as antiproliferative agents |
| 06/22/2006 | CA2589495A1 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
| 06/22/2006 | CA2589493A1 Combination therapy comprising telmisartan and hydrochlorothiazide |
| 06/22/2006 | CA2589363A1 Spiro derivatives as lipoxygenase inhibitors |
| 06/22/2006 | CA2589359A1 Targeted iron chelator delivery system |
| 06/22/2006 | CA2589084A1 Inhibitors of akt activity |
| 06/22/2006 | CA2589051A1 Trycyclic heterocycles, their manufacture and use as pharmaceutical agents |
| 06/22/2006 | CA2588909A1 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
| 06/22/2006 | CA2588595A1 N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 06/22/2006 | CA2588567A1 N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 06/22/2006 | CA2588389A1 Substituted phenols as active agents inhibiting vegf production |
| 06/22/2006 | CA2588384A1 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| 06/22/2006 | CA2588162A1 Oxadiazole derivatives as dgat inhibitors |
| 06/22/2006 | CA2588042A1 Compositions and methods for pulmonary conditions |
| 06/22/2006 | CA2588017A1 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea |
| 06/22/2006 | CA2587934A1 Pyrrole derivatives having crth2 receptor antagonist activity |
| 06/22/2006 | CA2587932A1 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy |
| 06/22/2006 | CA2587639A1 Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| 06/22/2006 | CA2587595A1 Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof |
| 06/22/2006 | CA2587428A1 Manufacture process of organic compounds |
| 06/22/2006 | CA2587423A1 1-arylpyrazoles and their use as pesticides |
| 06/22/2006 | CA2586543A1 Pyrazolo-heteroaryl compounds useful to treat tnf-alpha and il-1 mediated diseases |
| 06/22/2006 | CA2585659A1 Cancer treatments |
| 06/22/2006 | CA2585560A1 Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome |
| 06/22/2006 | CA2584367A1 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| 06/22/2006 | CA2551486A1 Fused bicycloheterocycle substituted quinuclidine derivatives |
| 06/22/2006 | CA2530963A1 Phototherapy compositions and methods |
| 06/22/2006 | CA2529630A1 New derivatives of benzo[b]pyrano[3,2-h] acridin-7-one cinnamates, their preparation process and the pharmaceutical compositions that contain them |
| 06/22/2006 | CA2509083A1 A medical device |
| 06/21/2006 | EP1672065A1 Protein expressed in nk cell |
| 06/21/2006 | EP1671980A2 Avermectin derivatives |
| 06/21/2006 | EP1671979A1 New Cristal Form of Azithromycin |
| 06/21/2006 | EP1671973A2 Allosteric adenosine receptor modulators |
| 06/21/2006 | EP1671972A1 Octahydropyrrolo[3,4-c]pyrrole derivatives |
| 06/21/2006 | EP1671969A2 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/21/2006 | EP1671967A1 1-Arylpyrazoles and their use as pesticides |
| 06/21/2006 | EP1671965A2 Oxacarbocyclic oligomers of fumaric acid |
| 06/21/2006 | EP1671963A1 Endurance improving agent |
| 06/21/2006 | EP1671962A1 Novel fused heterocyclic compound and use thereof |
| 06/21/2006 | EP1671957A1 Thiadiazoline derivatives |
| 06/21/2006 | EP1671950A1 Cinnamoyl derivatives and use thereof |
| 06/21/2006 | EP1671949A2 Substituted phenylamines and pyridinylamines |
| 06/21/2006 | EP1671948A1 Cinnamoyl compound and use of the same |
| 06/21/2006 | EP1671943A1 Preparation of EKB-569 and related intermediates |
| 06/21/2006 | EP1671942A1 Aerosol formulation comprising levalbuterol L-tartrate salt |
| 06/21/2006 | EP1671655A1 Gene therapy for skin diseases using needle free syringe |
| 06/21/2006 | EP1671653A1 Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared |
| 06/21/2006 | EP1671652A1 Use of chitosan for the treatment of pruritus |
| 06/21/2006 | EP1671651A1 Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonists |